Marksans Pharma share price
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
About Marksans Pharma
Marksans Pharma Limited is a Mumbai-based drug maker that develops, manufactures and distributes over-the-counter (OTC) medicines, which are sold without a prescription, and prescription (Rx) medicines.1 Its OTC business includes store brands: medicines it makes for supermarkets, pharmacy chains and other retailers to sell under their own labels in the United States, the United Kingdom and Australia.234
It operates in over 60 countries, and its principal regions are the United States and North America, the United Kingdom and Europe, and Australia and New Zealand.15 Its subsidiaries include Time-Cap Laboratories in the United States, Bell, Sons & Co. and Relonchem in the United Kingdom, and Nova Pharmaceuticals Australasia, 60% owned, in Australia and New Zealand.6 In the UK it ranks among the top 5 Indian pharmaceutical companies by revenue, the company says.3 In Australia, Nova sells branded prescription medicines under its Nova Pharma division, whose brands include Vymaze and Rinidate.47
It was incorporated in 1992.8 It bought Nova Pharmaceuticals Australasia in 2005, Relonchem in 2008, Time-Cap Laboratories in 2015 and Access Healthcare, based in Dubai, in 2022.910 Its founder, Mark Saldanha, is Chairman and Managing Director; the promoters, including him and Sandra Saldanha, held 43.9% of the shares at the end of June 2026, and the healthcare investor OrbiMed held 8.6%.111213
Marksans Pharma key points
Results
- In the quarter to Jun 2026, consolidated revenue from operations rose 35.6% from a year earlier to ₹840.8 crore, or 28.5% excluding ₹44 crore from the newly acquired QliniQ.1415
- In the quarter to Jun 2026, EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹213 crore and profit after tax ₹159 crore, each the highest for any quarter; the EBITDA margin was 25.3%, against 16.1% a year earlier.16
- In the year to Mar 2026, consolidated revenue from operations rose 12.5% to ₹2,951 crore, EBITDA was ₹601 crore, a margin of 20.4%, and profit after tax ₹420 crore; total income, including other income, passed ₹3,000 crore for the first time, at ₹3,033 crore.1718
- In the year to Mar 2026, the company generated operating cash flow of ₹458 crore and free cash flow of ₹328 crore and had no debt; its cash passed ₹1,000 crore for the first time in June 2026, at ₹1,058 crore.1920
Revenue mix
- Revenue by type, year to Mar 20262122OTC revenue was ₹2,361 crore.
Item year to Mar 2026 OTC 80.0% Prescription (Rx) 20.0% - Store brands made up about 85% of OTC revenue in the year to Mar 2026, on the company's approximate split.23
- In the UK, the company's business is about 55% prescription and 45% OTC, the company said on its call of 13 Aug 2026.24
Where revenue comes from
- Revenue by region, quarter to Jun 2026, change from a year earlier25
Item quarter to Jun 2026 US and North America ₹377 crore, up 15.1% UK and Europe ₹356 crore, up 74.7% Australia and New Zealand ₹88 crore, up 53.7% Rest of the world ₹20 crore, down 36.8% - In the year to Mar 2026, US and North America revenue rose 24% to ₹1,533 crore, about 52% of the total; UK and Europe was the second-largest market at about 34%.2627
- Australia and New Zealand revenue rose 20% to ₹303 crore in the year to Mar 2026, when Nova Pharma launched 11 prescription brands there.2829
Plants and capacity
- The company has 4 plants, 2 at Verna in Goa, India, and 1 each at Southport, UK, and Farmingdale, New York, with capacity of about 26 billion units a year.3031
- Annual capacity by location32
India, both Goa plants 2.4 billion capsules, 14 billion tablets Farmingdale, USA 6 billion tablets and hard capsules Southport, UK 2 billion bottles, 1 billion tubes, 1 billion sachets - Utilisation at the Goa facility being ramped up approached 50% in the year to Mar 2026, leaving room for higher volumes without large new capital spending, the company said.33
Customers and partners
- In the United States, Time-Cap Laboratories' retail customers include Walmart, Walgreens, CVS, Dollar General, Target and Kroger.34
Research and development
- Spending on research and development (R&D) was ₹89 crore in the year to Mar 2026, about 3% of consolidated revenue, and ₹23.2 crore, 2.8% of revenue, in the quarter to Jun 2026.3536
- At 31 Mar 2026, the company held more than 350 approved ANDAs (US applications to sell a generic medicine) and marketing authorisations (licences to sell a medicine in a country), with over 30 filings awaiting approval and more than 200 products in development.37
- In its presentation of 12 Aug 2026, the company said it plans to file more than 200 products in the UK over the next 4 years.38
What the company expects
- On its earnings call of 13 Aug 2026, the company said it remained on target to reach ₹4,000 crore of revenue within the next 2 years, with growth expected from all its regions.39
- On its earnings call of 13 Aug 2026, the company said it hoped Europe could reach about ₹1,000 crore of revenue within 5 years, mostly through acquisitions.40
- On its earnings call of 13 Aug 2026, the company said its next goal for US revenue was $300 million, followed by $400 million over about 5 years.41
Recent events
- On 20 Jul 2026, the company completed its purchase of all of ABCnow GmbH, a German company with prescription and OTC medicines; in its presentation of 12 Aug 2026, it said consolidation would start in the quarter after the quarter to Jun 2026.424344
- On 16 Jun 2026, the company completed its purchase of all of QliniQ B.V., a Netherlands company selling niche pharmaceuticals and medical devices, for €7,500,000; QliniQ's revenue was €9.35 million in the year to Dec 2025.454647
- On 9 Jun 2026, India Ratings and Research affirmed its IND AA- credit rating on ₹195.75 crore of the company's bank loan facilities and raised the outlook to Positive from Stable.48
- On 7 Nov 2025, a US FDA inspection of the company's second Goa plant ended with zero Form 483 observations, the list of problems the inspectors record.49
Last updated
All 49 sources, each with its page
- 1. Annual report, 4 Aug 2026, page 4
- 2. Investor presentation, 12 Aug 2026, page 22
- 3. Annual report, 4 Aug 2026, page 29
- 4. Annual report, 4 Aug 2026, page 11
- 5. Exchange filing, 1 Jun 2026, page 3
- 6. Annual report, 4 Aug 2026, page 34
- 7. Investor presentation, 12 Aug 2026, page 17
- 8. Annual report, 4 Aug 2026, page 22
- 9. Annual report, 4 Aug 2026, page 5
- 10. Investor presentation, 12 Aug 2026, page 10
- 11. Investor presentation, 12 Aug 2026, page 45
- 12. Investor presentation, 12 Aug 2026, page 50
- 13. Annual report, 4 Aug 2026, page 21
- 14. Investor presentation, 12 Aug 2026, page 7
- 15. Investor presentation, 12 Aug 2026, page 49
- 16. Investor presentation, 12 Aug 2026, page 6
- 17. Annual report, 4 Aug 2026, page 8
- 18. Investor presentation, 12 Aug 2026, page 20
- 19. Annual report, 4 Aug 2026, page 8
- 20. Investor presentation, 12 Aug 2026, page 6
- 21. Investor presentation, 12 Aug 2026, page 21
- 22. Investor presentation, 12 Aug 2026, page 27
- 23. Investor presentation, 12 Aug 2026, page 22
- 24. Earnings call, 13 Aug 2026, page 14
- 25. Investor presentation, 12 Aug 2026, page 9
- 26. Annual report, 4 Aug 2026, page 29
- 27. Annual report, 4 Aug 2026, page 8
- 28. Annual report, 4 Aug 2026, page 29
- 29. Annual report, 4 Aug 2026, page 11
- 30. Annual report, 4 Aug 2026, page 30
- 31. Annual report, 4 Aug 2026, page 59
- 32. Annual report, 4 Aug 2026, page 12
- 33. Annual report, 4 Aug 2026, page 8
- 34. Annual report, 4 Aug 2026, page 11
- 35. Annual report, 4 Aug 2026, page 8
- 36. Earnings call, 13 Aug 2026, page 5
- 37. Annual report, 4 Aug 2026, page 11
- 38. Investor presentation, 12 Aug 2026, page 34
- 39. Earnings call, 13 Aug 2026, page 6
- 40. Earnings call, 13 Aug 2026, page 12
- 41. Earnings call, 13 Aug 2026, page 14
- 42. Exchange filing, 20 Jul 2026, page 1
- 43. Earnings call, 13 Aug 2026, page 12
- 44. Investor presentation, 12 Aug 2026, page 10
- 45. Exchange filing, 16 Jun 2026, page 1
- 46. Exchange filing, 1 Jun 2026, page 5
- 47. Exchange filing, 1 Jun 2026, page 2
- 48. Exchange filing, 9 Jun 2026, page 1
- 49. Exchange filing, 10 Nov 2025, page 1
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore.Marksans Pharma quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹321 Crdown 11.17%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹69 Crdown 24.90%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 21.5%
Revenue by quarter
Peak revenue ₹362 Cr, quarter to Mar 2026; lowest ₹299 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 309 | 312 | 299 | 320 | 320 | 340 | 362 | 321 |
| Net profit | 63 | 55 | 38 | 48 | 100 | 61 | 92 | 69 |
| Net margin | 20.5% | 17.8% | 12.6% | 15.0% | 31.1% | 17.9% | 25.4% | 21.5% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,341 Crup 14.23%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹301 Crup 59.71%
- Net margin
- 22.4%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹433 Cr, differs from its quarters added, ₹424 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216 | 295 | 424 | 433 | 600 | 658 | 655 | 853 | 1,174 | 1,341 |
| Net profit | 12 | 12 | 44 | 38 | 98 | 104 | 103 | 134 | 188 | 301 |
| Net margin | 5.7% | 4.2% | 10.3% | 8.7% | 16.4% | 15.8% | 15.7% | 15.7% | 16.0% | 22.4% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical Formulation, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2020: days before it are of the company before the change.Marksans Pharma PE ratio and valuation
Price to earnings
At or below today's level on 60% of 2,479 trading days over the last 10 years.
LowestHighest
Its median20.88Industry median27.77
Price to book
At or below today's level on 77% of 1,889 trading days since Nov 2018.
LowestHighest
Its median3.19Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 55% of 2,464 trading days over the last 10 years.
LowestHighest
Its median0.28%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −28.9% | +60.0% | −55.9% | 0.6% |
| 3 years | +31.1% | +43.0% | −8.6% | 0.4% |
| 5 years | +26.2% | +22.6% | +2.6% | 0.5% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
26 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 9 of the 15 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 26 funds holding Marksans Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 4
- CutCut. Funds that held fewer shares than at the end of the month before.
- 11
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 9
| Fund | |||
|---|---|---|---|
 Bandhan Small Cap FundBandhan Mutual Fund | 34,21,739 | 0.31% | ₹110.3 Cr |
 UTI Small Cap FundUTI Mutual Fund | 29,72,150 | 1.83% | ₹95.8 Cr |
 Kotak MNC FundKotak Mahindra Mutual Fund | 20,00,000 | 2.87% | ₹64.5 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 15,29,807 | 2.57% | ₹49.3 Cr |
| UTI Large & Mid Cap FundUTI Mutual Fund | 14,02,958 | 0.73% | ₹45.2 Cr |
| UTI Aggressive Hybrid FundUTI Mutual Fund | 12,04,953 | 0.60% | ₹38.8 Cr |
| UTI Healthcare FundUTI Mutual Fund | 10,00,000 | 2.25% | ₹32.2 Cr |
| Kotak Healthcare FundKotak Mahindra Mutual Fund | 6,25,000 | 2.44% | ₹20.1 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 5,82,076 | 0.78% | ₹18.8 Cr |
| UTI Multi Cap FundUTI Mutual Fund | 5,00,624 | 0.76% | ₹16.1 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Marksans Pharma insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Directors and key managers: no market trade · 1 off-market move
- Others: no market trade · 3 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Marksans Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Marksans Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 AstraZeneca Pharma IndiaASTRAZEN | 15,911 | 93.81 | 18.23 | +31.1% | −7.5% | 20.6% | 24.4% | 0.57% |
 Alembic PharmaceuticalsAPLLTD | 15,683 | 22.69 | 2.76 | +14.1% | +14.6% | 12.7% | 11.8% | 1.50% |
 Natco PharmaNATCOPHARM | 15,348 | 13.41 | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.58% |
 Jubilant PharmovaJUBLPHARMA | 14,714 | 41.79 | 2.07 | +16.3% | −23.5% | 5.3% | 7.3% | 0.54% |
 CORONA RemediesCORONA | 13,147 | 63.51 | 16.33 | – | – | 28.3% | 31.8% | 0.47% |
 Concord BiotechCONCORDBIO | 13,031 | 46.14 | 6.28 | +4.0% | −12.8% | 14.5% | 15.9% | 0.61% |
 Akums Drugs and PharmaceuticalsAKUMS | 11,517 | 39.48 | 3.48 | +9.2% | −14.6% | 9.2% | 12.0% | 0.41% |
 Strides Pharma ScienceSTAR | 9,851 | 15.97 | 2.88 | +11.3% | +55.3% | 20.0% | 13.9% | 0.47% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Marksans Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.90 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 20 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.90 |
| 1 Aug 2025 | Final | ₹0.80 |
| 17 Sep 2024 | Final | ₹0.60 |
| 7 Jun 2023 | Final | ₹0.50 |
| 19 Aug 2022 | Final | ₹0.25 |
| 15 Sep 2021 | Final | ₹0.25 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Marksans Pharma announcements
Oct 2026
26 Oct · Analysts
Sep 2026
17 Sep · General Updates
1 Sep · Analysts
Aug 2026
Marksans Pharma share price by year
Each calendar year to 2025.Marksans Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 180.29 | −39.2% | 304.65 | 164.06 |
| 2024 | 296.65 | +84.1% | 353.40 | 132.95 |
| 2023 | 161.10 | +176.6% | 170.65 | 58.30 |
| 2022 | 58.25 | −3.2% | 64.05 | 39.45 |
| 2021 | 60.15 | −0.8% | 94.55 | 49.35 |
| 2020 | 60.65 | +263.2% | 64.90 | 10.45 |
| 2019 | 16.70 | −40.0% | 28.20 | 12.60 |
| 2018 | 27.85 | −30.3% | 48.75 | 24.65 |
| 2017 | 39.95 | +0.3% | 56.45 | 35.20 |
| 2016 | 39.85 | −61.9% | 104.60 | 34.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 305.90 | 318.80 | 300.00 | 315.35 | 313.50 | 20,08,915 | 38.7% |
| 28 Oct 2026 | 301.10 | 308.25 | 298.65 | 305.20 | 304.22 | 14,05,300 | 48.0% |
| 27 Oct 2026 | 297.60 | 303.10 | 294.80 | 300.10 | 300.65 | 10,26,508 | 46.9% |
| 26 Oct 2026 | 286.90 | 298.75 | 285.10 | 296.65 | 293.88 | 11,71,919 | 42.8% |
| 23 Oct 2026 | 292.00 | 295.35 | 282.70 | 286.90 | 287.30 | 14,14,619 | 53.0% |
| 22 Oct 2026 | 294.00 | 298.00 | 291.25 | 294.45 | 294.52 | 8,17,786 | 42.8% |
| 21 Oct 2026 | 304.65 | 306.75 | 293.60 | 298.15 | 298.28 | 13,85,441 | 47.8% |
| 19 Oct 2026 | 311.00 | 314.50 | 302.00 | 303.05 | 307.30 | 8,17,392 | 43.9% |
| 16 Oct 2026 | 308.10 | 313.50 | 306.00 | 311.00 | 310.02 | 7,67,998 | 44.4% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 15 Jan 2016 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 11 Mar 2008 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- MARKSANS
- BSE code
- 524404
- ISIN
- INE750C01026
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- TASCPHARMA
- Website
- www.marksanspharma.com
- CIN
- L24110MH1992PLC066364
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1992
- Registered office
- GRANDEUR, 11th Floor, Veera Desai Extention Road, Opp. Gundeecha Symphony, Oshiwara, Andheri (W), Mumbai 400053, Maharashtra
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments